JP2000511425A5 - - Google Patents

Download PDF

Info

Publication number
JP2000511425A5
JP2000511425A5 JP1997543071A JP54307197A JP2000511425A5 JP 2000511425 A5 JP2000511425 A5 JP 2000511425A5 JP 1997543071 A JP1997543071 A JP 1997543071A JP 54307197 A JP54307197 A JP 54307197A JP 2000511425 A5 JP2000511425 A5 JP 2000511425A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1997543071A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000511425A (ja
JP4318752B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/009610 external-priority patent/WO1997045450A1/en
Publication of JP2000511425A publication Critical patent/JP2000511425A/ja
Publication of JP2000511425A5 publication Critical patent/JP2000511425A5/ja
Application granted granted Critical
Publication of JP4318752B2 publication Critical patent/JP4318752B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP54307197A 1996-05-31 1997-05-30 抗エンドグリンモノクローナル抗体および抗血管新生治療におけるその使用 Expired - Lifetime JP4318752B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65595396A 1996-05-31 1996-05-31
US08/655,953 1996-05-31
PCT/US1997/009610 WO1997045450A1 (en) 1996-05-31 1997-05-30 Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy

Publications (3)

Publication Number Publication Date
JP2000511425A JP2000511425A (ja) 2000-09-05
JP2000511425A5 true JP2000511425A5 (enExample) 2005-01-13
JP4318752B2 JP4318752B2 (ja) 2009-08-26

Family

ID=24631047

Family Applications (1)

Application Number Title Priority Date Filing Date
JP54307197A Expired - Lifetime JP4318752B2 (ja) 1996-05-31 1997-05-30 抗エンドグリンモノクローナル抗体および抗血管新生治療におけるその使用

Country Status (8)

Country Link
US (2) US5928641A (enExample)
EP (1) EP0938505B1 (enExample)
JP (1) JP4318752B2 (enExample)
AT (1) ATE214075T1 (enExample)
CA (1) CA2256413C (enExample)
DE (1) DE69710911T2 (enExample)
ES (1) ES2169864T3 (enExample)
WO (1) WO1997045450A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
DE19845798A1 (de) * 1998-09-29 2000-04-13 Schering Ag Verwendung von Neoangiogenese-Markern für Diagnose und Therapie von Tumoren, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung
WO2000042973A2 (en) * 1999-01-22 2000-07-27 The Burnham Institute Homing pro-apoptotic conjugates and methods of using same
AU2006203034B2 (en) * 2000-02-10 2006-09-07 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
CA2398901C (en) * 2000-02-10 2010-11-16 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
DE10043481A1 (de) * 2000-09-04 2002-04-11 Vectron Therapeutics Ag Imt Humaner Antikörper gegen Endoglin (CD105) und seine Verwendung
JP2003021631A (ja) * 2001-05-10 2003-01-24 Chugai Pharmaceut Co Ltd 骨転移抑制剤のスクリーニング方法
EP1432447A2 (en) * 2001-09-27 2004-06-30 The Board Of Regents, The University Of Texas System Combined compositions and methods for tumor vasculature coagulation and treatment
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
WO2005044853A2 (en) * 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
AP2740A (en) * 2003-08-01 2013-09-30 Genentech Inc Anti-VEGF antibodies
EP1533617A1 (en) * 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
WO2006020979A2 (en) * 2004-08-13 2006-02-23 Yale University Factor vii conjugates for selectively treating neovascularization disorders
DK1804836T3 (da) 2004-09-24 2011-01-24 Beth Israel Hospital Fremgangsmåder til diagnosticering og behandling af graviditetskomplikationer
US7740849B2 (en) * 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
EP1839057B1 (en) * 2004-12-15 2010-08-25 Beth Israel Deaconess Medical Center Nucleic acids and polypeptides useful for diagnosing and treating complications of pregnancy
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
EP3181580A1 (en) 2006-11-02 2017-06-21 Acceleron Pharma Inc. Alk1 receptor and ligand antagonists and uses thereof
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗-vegf抗體
MX2010011998A (es) 2008-05-02 2011-04-11 Acceleron Pharma Inc Metodos y composiciones de pericitos para regular la angiogenesis y composicion de pericapilar.
US20100082438A1 (en) * 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring
US8221753B2 (en) * 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
ES2657497T3 (es) 2009-08-17 2018-03-05 Tracon Pharmaceuticals, Inc. Terapia de combinación de cáncer con anticuerpos antiendoglina y agentes anti-VEGF
PT2510012T (pt) * 2009-12-09 2017-07-13 Bayer Pharma AG Anticorpos anti-c4.4a e utilizações dos mesmos
JP2014508523A (ja) * 2011-02-23 2014-04-10 ヘルス リサーチ インコーポレイテッド 抗エンドグリン抗体及び新規ヒト/マウスキメラエンドグリンを発現するノックインマウス
US9255595B2 (en) * 2011-04-29 2016-02-09 Bae Systems Information And Electronic Systems Integration Inc. Optical dome bezel
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
EP3008667B1 (en) 2013-06-14 2019-01-16 Agilent Technologies, Inc. System and method for facilitating manual sorting of objects
GB201402006D0 (en) 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
AU2015346444A1 (en) 2014-11-12 2017-05-04 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
WO2017053807A2 (en) 2015-09-23 2017-03-30 Genentech, Inc. Optimized variants of anti-vegf antibodies
RU2607029C1 (ru) * 2015-10-20 2017-01-10 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ / ФГБУ "РНЦРХТ" Минздрава России ШТАММ ГИБРИДНЫХ КУЛЬТИВИРУЕМЫХ КЛЕТОК ЖИВОТНЫХ Mus musculus L. - EN-4C9 - ПРОДУЦЕНТ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ ПРОТИВ ЭНДОГЛИНА (CD105) ЧЕЛОВЕКА
CN106928359B (zh) * 2015-12-30 2020-10-13 广西医科大学 一种CD105纳米抗体Nb59
CN106928355B (zh) * 2015-12-30 2020-09-29 广西医科大学 一种CD105纳米抗体Nb184
US11136581B2 (en) 2016-06-24 2021-10-05 University Of South Carolina Inhibin as targetable regulators of angiogenesis
EP3900733A1 (en) 2020-04-24 2021-10-27 Derma Innovate S.L. Src kinase activators and eng function inhibitors as enhancers of skin homeostasis/regeneration and hair growth
CN116063496B (zh) * 2022-08-15 2023-10-24 营龄(武汉)生物科技有限公司 载药的人血白蛋白联合单克隆抗体在制备药物组合物中的用途
CN115991773B (zh) * 2022-08-15 2023-11-17 营龄(武汉)生物科技有限公司 一种含有人血白蛋白的药物组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94389A0 (en) * 1989-06-01 1991-03-10 Health Research Inc Monoclonal antibody reactive to a unique antigen widely present on various human leukemia and lymphoma cells and method of using same for diagnosis and treatment
US5660827A (en) * 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin

Similar Documents

Publication Publication Date Title
JP2000502280A5 (enExample)
JP2001506876A5 (enExample)
JP2001503840A5 (enExample)
JP2000500076A5 (enExample)
JP2002514060A5 (enExample)
JP2000506111A5 (enExample)
JP2001509135A5 (enExample)
JP2000500055A5 (enExample)
JP2000500026A5 (enExample)
JP2000500874A5 (enExample)
JP2000502425A5 (enExample)
JP2000502485A5 (enExample)
JP2000502568A5 (enExample)
JP2000503848A5 (enExample)
JP2000511425A5 (enExample)
JP2000502570A5 (enExample)
JP2000500912A5 (enExample)
JP2000501876A5 (enExample)
JP2001527686A5 (enExample)
JP2000505908A5 (enExample)
JP2000502316A5 (enExample)
JP2000500857A5 (enExample)
JP2000502714A5 (enExample)
JP2001500910A5 (enExample)
JP2000500318A5 (enExample)